[go: up one dir, main page]

NO20073914L - Biologisk aktive peptider - Google Patents

Biologisk aktive peptider

Info

Publication number
NO20073914L
NO20073914L NO20073914A NO20073914A NO20073914L NO 20073914 L NO20073914 L NO 20073914L NO 20073914 A NO20073914 A NO 20073914A NO 20073914 A NO20073914 A NO 20073914A NO 20073914 L NO20073914 L NO 20073914L
Authority
NO
Norway
Prior art keywords
biologically active
active peptides
disclosed
nucleic acids
pharmaceutical formulation
Prior art date
Application number
NO20073914A
Other languages
English (en)
Inventor
Wai Ming Wong
Kong Lam
Original Assignee
Cms Peptides Patent Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20073914L publication Critical patent/NO20073914L/no
Application filed by Cms Peptides Patent Holding Co filed Critical Cms Peptides Patent Holding Co

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

30 vesentlig rene og biologisk aktive peptider er beskrevet. Nukleinsyrer som har sekvenser som koder for de biologisk aktive peptidene og farmasøytiske formulering som produseres derfiia, er også beskrevet.
NO20073914A 2001-07-13 2007-07-25 Biologisk aktive peptider NO20073914L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90449201A 2001-07-13 2001-07-13
PCT/GB2002/003203 WO2003006492A2 (en) 2001-07-13 2002-07-11 Biologically active peptides

Publications (1)

Publication Number Publication Date
NO20073914L true NO20073914L (no) 2004-03-10

Family

ID=25419251

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20040134A NO332061B1 (no) 2001-07-13 2004-01-12 Renset peptid for bruk som medikament, farmasoytisk sammensetning samt fremgangsmate for fremstilling
NO20073914A NO20073914L (no) 2001-07-13 2007-07-25 Biologisk aktive peptider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20040134A NO332061B1 (no) 2001-07-13 2004-01-12 Renset peptid for bruk som medikament, farmasoytisk sammensetning samt fremgangsmate for fremstilling

Country Status (23)

Country Link
EP (3) EP1947109A3 (no)
JP (3) JP4213581B2 (no)
KR (2) KR100889993B1 (no)
AT (2) ATE414099T1 (no)
AU (1) AU2002319423B2 (no)
BR (1) BR0210252A (no)
CA (2) CA2452417C (no)
DE (2) DE60236330D1 (no)
DK (2) DK1790655T3 (no)
ES (2) ES2345842T3 (no)
IL (2) IL159827A0 (no)
MX (1) MXPA03011190A (no)
MY (1) MY138219A (no)
NO (2) NO332061B1 (no)
NZ (3) NZ553507A (no)
PL (2) PL211884B1 (no)
PT (2) PT1790655E (no)
RU (2) RU2425053C2 (no)
SA (1) SA04240478B1 (no)
SG (2) SG142165A1 (no)
UA (1) UA83989C2 (no)
WO (1) WO2003006492A2 (no)
ZA (2) ZA200401108B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1223602C (zh) 2001-07-13 2005-10-19 一泰医药研究（深圳）有限公司 序列号11的生物活性肽
US20060167229A1 (en) * 2002-12-18 2006-07-27 Wai Ming Wong Biologically active peptide conjugates
TWI322815B (en) * 2003-06-26 2010-04-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide comprising tyrosyl-seryl-valine (ysv)
TWI353252B (en) * 2004-04-28 2011-12-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide vapeehptllteaplnpk der
CN1799623B (zh) * 2005-01-05 2011-01-26 康哲医药研究(深圳)有限公司 生物活性肽在制备用于防治关节炎的药物中的用途
RU2423375C2 (ru) 2005-07-26 2011-07-10 СиЭмЭс ПЕПТАЙДЗ ПЭЙТЕНТ ХОЛДИНГ КОМПАНИ ЛИМИТЕД Новые биологически активные пептиды и их новое применение
GB0918579D0 (en) * 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
RU2429005C1 (ru) * 2010-10-07 2011-09-20 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Способ стимуляции противоопухолевой активности цитотоксических эффекторов иммунной системы
RU2615908C1 (ru) * 2016-05-16 2017-04-11 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс
TWI890506B (zh) * 2024-06-27 2025-07-11 開曼群島商味丹國際（控股）有限公司 具有抑制ace活性之胜肽及其組合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242821A (en) 1989-07-10 1993-09-07 Valio, Finnish Co-Operative Dairies' Association Lactococcus promoter and signal sequences for expression in bacteria
IT1231156B (it) 1989-07-19 1991-11-19 Eniricerche Spa Espressione e secrezione di interleuchina 1 beta umana matura in bacillus subtilis e mezzi e metodi per il suo ottenimento.
WO1991009613A1 (en) * 1989-12-22 1991-07-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Synthetic peptides as modulators of functional responses of intact cells
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
DE69433299T2 (de) 1993-06-15 2004-09-09 E.I. Du Pont De Nemours And Co., Wilmington Rekombinante spinnerseide analoge
JP3286420B2 (ja) 1993-09-28 2002-05-27 株式会社ユニシアジェックス 内燃機関の吸排気弁駆動制御装置
AU2631695A (en) 1994-06-17 1996-01-15 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method for introduction of genetic material into microorganisms and transformants obtained therewith
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
ATE273322T1 (de) 1995-10-24 2004-08-15 Chemo Sero Therapeut Res Inst Tfpi-verwandte peptide die das wachstums von glatten muskelzellen inhibieren
GB9606016D0 (en) * 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
SE9603468D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
GB9710762D0 (en) * 1997-05-23 1997-07-23 Cancer Res Inst Royal Binding complexes
EP1015612B1 (en) 1997-05-27 2005-01-26 Hanil Synthetic Fiber Co., Ltd. Process for preparing recombinant proteins using highly efficient expression vector from saccharomyces cerevisiae
KR19990024297A (ko) 1997-08-07 1999-04-06 오종석 인체 구강내 치태형성을 억제하는 신규한 유산균
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US6245427B1 (en) 1998-07-06 2001-06-12 DüZGüNES NEJAT Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
JP2002523114A (ja) * 1998-08-31 2002-07-30 ユニバーシテイ オブ ワシントン バイオポリマーの分析のための安定なアイソトープ代謝性ラベリング
US6413530B1 (en) * 1999-04-21 2002-07-02 University Of Florida Research Foundation, Inc. Pesticidal peptides
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
AU1197001A (en) * 1999-10-29 2001-05-14 Institute For Applied Biomedicine B cell clonal toxins and methods for using the same

Also Published As

Publication number Publication date
EP1478659A2 (en) 2004-11-24
EP1790655A2 (en) 2007-05-30
CA2452417C (en) 2013-08-20
IL159827A0 (en) 2004-06-20
EP1790655A3 (en) 2007-10-10
ATE466871T1 (de) 2010-05-15
EP1790655B1 (en) 2010-05-05
CA2707767A1 (en) 2003-01-23
ATE414099T1 (de) 2008-11-15
PL211884B1 (pl) 2012-07-31
NZ529879A (en) 2007-12-21
WO2003006492A2 (en) 2003-01-23
PL368059A1 (en) 2005-03-21
NZ544079A (en) 2007-10-26
ZA200401108B (en) 2006-05-31
NZ553507A (en) 2008-07-31
ES2316586T3 (es) 2009-04-16
HK1066552A1 (en) 2005-03-24
KR20040019058A (ko) 2004-03-04
NO20040134L (no) 2004-03-10
EP1478659B1 (en) 2008-11-12
KR100889993B1 (ko) 2009-03-25
SG185137A1 (en) 2012-11-29
MY138219A (en) 2009-05-29
RU2425053C2 (ru) 2011-07-27
UA83989C2 (ru) 2008-09-10
AU2002319423B2 (en) 2008-02-14
DK1478659T3 (da) 2009-01-05
IL184227A0 (en) 2007-10-31
EP1947109A2 (en) 2008-07-23
KR100889992B1 (ko) 2009-03-25
ZA200509838B (en) 2007-11-28
IL184227A (en) 2010-06-16
WO2003006492A3 (en) 2003-12-31
SG142165A1 (en) 2008-05-28
PT1790655E (pt) 2010-07-09
JP2007312785A (ja) 2007-12-06
BR0210252A (pt) 2004-09-14
KR20070070258A (ko) 2007-07-03
CA2707767C (en) 2013-09-03
MXPA03011190A (es) 2004-10-28
JP4316651B2 (ja) 2009-08-19
JP2004533846A (ja) 2004-11-11
JP4213581B2 (ja) 2009-01-21
ES2345842T3 (es) 2010-10-04
PT1478659E (pt) 2009-01-02
JP2008263993A (ja) 2008-11-06
CA2452417A1 (en) 2003-01-23
PL208666B1 (pl) 2011-05-31
RU2007108896A (ru) 2008-09-20
DE60229883D1 (de) 2008-12-24
DK1790655T3 (da) 2010-08-23
SA04240478B1 (ar) 2007-07-31
EP1947109A3 (en) 2008-10-01
RU2305107C2 (ru) 2007-08-27
HK1098767A1 (en) 2007-07-27
DE60236330D1 (de) 2010-06-17
RU2004104335A (ru) 2005-03-27
NO332061B1 (no) 2012-06-11

Similar Documents

Publication Publication Date Title
NO20073914L (no) Biologisk aktive peptider
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK1329458T5 (da) Peptider som sænker blodglucoseniveauer
BR0012759A (pt) Neurotoxinas recombinantes ativáveis
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
ATE504308T1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
ATE455092T1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
IL173929A0 (en) Analogues of kahalalide f and pharmaceutical compositions containing the same
WO2001092468A3 (en) Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
TW200611913A (en) Biologically active peptides (Ⅲ)
DE60039708D1 (de) Menschliches chordin und polynukleotiden die dafür kodieren
DE60141994D1 (de) 13-substituierte Methacyclinverbindungen
CA2530618A1 (en) Novel calcium channel
IT1298437B1 (it) Procedimento per la produzione di proteine/peptidi tossici
BR0107799A (pt) Proteìna de interação de wt1 wtip
IT1307333B1 (it) Peptidi derivati dall'allergene parj2 del polline di parietariajudaica.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application